Neumora Therapeutics (NMRA) Free Cash Flow (2022 - 2026)

Neumora Therapeutics' Free Cash Flow history runs 5 years deep, the most recent figure standing at -$46.4 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 21.94% year-over-year to -$46.4 million in Q1 2026; TTM through Mar 2026 was -$193.4 million, a 3.03% increase from a year earlier, with the FY2025 full-year figure at -$206.4 million, down 12.85% from the prior year.
• Free Cash Flow grew to -$46.4 million in Q1 2026 per NMRA's latest filing, from -$48.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$30.9 million in Q4 2022 and bottomed at -$59.4 million in Q1 2025.
• The 5-year median for Free Cash Flow is -$47.2 million (2023), against an average of -$45.0 million.
• Biggest YoY gain for Free Cash Flow was 29.97% in 2024; the steepest drop was 81.03% in 2024.
• Year by year, Free Cash Flow stood at -$30.9 million in 2022, then tumbled by 66.89% to -$51.5 million in 2023, then gained by 2.23% to -$50.3 million in 2024, then advanced by 4.74% to -$48.0 million in 2025, then increased by 3.23% to -$46.4 million in 2026.
• Per Business Quant, the three latest NMRA Free Cash Flow figures stand at -$46.4 million (Q1 2026), -$48.0 million (Q4 2025), and -$46.6 million (Q3 2025).